Australia's Sigma Unlikely To Be Saved By iNova Investors
This article was originally published in PharmAsia News
Reports predicting Australia's financially troubled Sigma Pharmaceuticals might be bought and saved are being dashed by closer looks at possible suitors
You may also be interested in...
With around half the French population vitamin D deficient, a group of medical experts say mass supplementation is a low cost and low risk intervention which could save lives and curb the spread of COVID-19.
UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.
Biohaven Pharmaceuticals developed six different value-based contracting options to support the launch of acute migraine therapy, Nurtec ODT. Despite contract complexity and lingering regulatory risk, payers are aggressively pursuing value-based contracts, leading even small biopharmas to invest in strong health economics capabilities.